Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No need to change post-operative treatment for lung cancer, says clinical scientist

24.09.2003


Post-operative chemotherapy in non-small cell lung cancer (NSCLC) looks like an attractive proposition to prevent the cancer recurring, said Professor Nick Thatcher, of the Christie Hospital, Manchester, UK at the ECCO-12 conference in Copenhagen today (Tuesday 23 September). But the recent IALT study, which is said to demonstrate a survival advantage for patients given adjuvant treatment, was statistically unreliable and needed to be taken in context, he said.



"A large body of evidence – 17 cisplatin trials as opposed to 1, the IALT study -demonstrated no survival advantage with the use of cisplatin-based adjuvant chemotherapy", said Professor Thatcher.

A meta-analysis of 14 trials of adjuvant (post resection cisplatin therapy) in NSCLC not only showed no survival benefit with chemotherapy, said Professor Thatcher, but with adjuvant radiotherapy (which was included in the IALT study) there was a survival detriment, 7% more people treated dying over 2 years. Three other more recent randomised cisplatin trials had also failed to show a survival benefit among patients receiving adjuvant chemotherapy in NSCLC, he said.


In the case of the IALT study, a probable survival benefit of 4.1% was suggested at 5 years in those who received adjuvant cisplatin compared with the no-chemotherapy control arm. "But there were only 1,867 patients in the trial, as against the intended 3300", said Professor Thatcher. "This means that statistically the result is less strong than it should have been. Secondly more post-operative radiotherapy was given to patients in the control arm, possibly reducing the control survival disproportionately".

"It is a shame when change of practice is undertaken on the basis of one unconfirmed result. A further trial or meta-analysis is ideally needed to determine the confidence of the result" said Professor Thatcher. "Although it is tempting to get excited about one positive result, it is vital that it should be properly validated by subsequent research. Furthermore, it is important to interpret trial results, not just in terms of ’p values’ but in terms of the confidence intervals which in the IALT trial fall within the range of all the other negative trials."

Mary Rice | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>